BRAF and neoplasm: We then conducted a prospective blinded validation of the targeted cfDNA panel via an inter-laboratory comparison of key oncogenes identified with tumor tissue using direct DNA sequencing (KRAS and BRAF) or hotspot analysis (KIT) to a second laboratory performing digital sequencing of cfDNA in corresponding plasma samples, while keeping the latter blind to the PCR reference standard results.